Cargando…

Evaluation of efficacy of Valsalva for attenuating needle puncture pain in first time nonremunerated voluntary plateletpheresis donors: A prospective, randomized controlled trial

BACKGROUND: Plateletpheresis is generally safe but may have adverse reactions. Adverse reactions can negatively influence donor recruitment and retention. Valsalva is a proven method of attenuating pain caused by venipuncture. AIMS: The aim was to evaluate the efficacy of the Valsalva maneuver on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivastava, Anubha, Kumar, Sanjay, Agarwal, Anil, Khetan, Dheeraj, Katharia, Rahul, Mishra, Prabhaker, Khati, Shikha, Gautam, Sujeet, Sandeep, Khuba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294442/
https://www.ncbi.nlm.nih.gov/pubmed/34349460
http://dx.doi.org/10.4103/ajts.AJTS_95_20
_version_ 1783725236007469056
author Srivastava, Anubha
Kumar, Sanjay
Agarwal, Anil
Khetan, Dheeraj
Katharia, Rahul
Mishra, Prabhaker
Khati, Shikha
Gautam, Sujeet
Sandeep, Khuba
author_facet Srivastava, Anubha
Kumar, Sanjay
Agarwal, Anil
Khetan, Dheeraj
Katharia, Rahul
Mishra, Prabhaker
Khati, Shikha
Gautam, Sujeet
Sandeep, Khuba
author_sort Srivastava, Anubha
collection PubMed
description BACKGROUND: Plateletpheresis is generally safe but may have adverse reactions. Adverse reactions can negatively influence donor recruitment and retention. Valsalva is a proven method of attenuating pain caused by venipuncture. AIMS: The aim was to evaluate the efficacy of the Valsalva maneuver on the attenuation of needle pain and donor anxiety. SETTINGS AND DESIGN: This prospective randomized controlled trial was conducted between November 2015 and April 2016 at the Department of Transfusion Medicine. SUBJECTS AND METHODS: One-hundred and sixty consecutive donors were grouped into control group (C) and Valsalva group (V) each of sample size 80. The Valsalva group performed a Valsalva maneuver and control did nothing before the venipuncture. Anxiety and pain were scored using a 10 cm visual analog scale (VAS). Severity was graded as VAS = 0 defines no pain and anxiety, VAS = 1–3 as mild pain and anxiety, VAS = 4–6 as moderate pain and anxiety, VAS = 7–9 as severe pain and anxiety, whereas VAS = 10 denotes extreme pain and anxiety. STATISTICAL ANALYSIS: Statistical Package for Social Sciences, version 23 was used for analysis. Independent samples t-test/Mann–Whitney U-test was used to compare between treatment and control group, whereas the Wilcoxon signed-rank test was used to test the difference between pre- and postobservations. RESULTS: In the Valsalva group, post-Valsalva anxiety levels were significantly reduced to (1 [0–2]) from their pre-Valsalva values of (2 [0–3]); (P < 0.001). Pain was significantly lower (2[1-2]) in Valsalva group compared to control (4[2–5]); (P < 0.001). CONCLUSIONS: Valsalva reduced both severity of venipuncture pain and anxiety. Valsalva can be performed by donors as it is an easy, painless, and nonpharmacological method of pain and anxiety attenuation.
format Online
Article
Text
id pubmed-8294442
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-82944422021-08-03 Evaluation of efficacy of Valsalva for attenuating needle puncture pain in first time nonremunerated voluntary plateletpheresis donors: A prospective, randomized controlled trial Srivastava, Anubha Kumar, Sanjay Agarwal, Anil Khetan, Dheeraj Katharia, Rahul Mishra, Prabhaker Khati, Shikha Gautam, Sujeet Sandeep, Khuba Asian J Transfus Sci Original Article BACKGROUND: Plateletpheresis is generally safe but may have adverse reactions. Adverse reactions can negatively influence donor recruitment and retention. Valsalva is a proven method of attenuating pain caused by venipuncture. AIMS: The aim was to evaluate the efficacy of the Valsalva maneuver on the attenuation of needle pain and donor anxiety. SETTINGS AND DESIGN: This prospective randomized controlled trial was conducted between November 2015 and April 2016 at the Department of Transfusion Medicine. SUBJECTS AND METHODS: One-hundred and sixty consecutive donors were grouped into control group (C) and Valsalva group (V) each of sample size 80. The Valsalva group performed a Valsalva maneuver and control did nothing before the venipuncture. Anxiety and pain were scored using a 10 cm visual analog scale (VAS). Severity was graded as VAS = 0 defines no pain and anxiety, VAS = 1–3 as mild pain and anxiety, VAS = 4–6 as moderate pain and anxiety, VAS = 7–9 as severe pain and anxiety, whereas VAS = 10 denotes extreme pain and anxiety. STATISTICAL ANALYSIS: Statistical Package for Social Sciences, version 23 was used for analysis. Independent samples t-test/Mann–Whitney U-test was used to compare between treatment and control group, whereas the Wilcoxon signed-rank test was used to test the difference between pre- and postobservations. RESULTS: In the Valsalva group, post-Valsalva anxiety levels were significantly reduced to (1 [0–2]) from their pre-Valsalva values of (2 [0–3]); (P < 0.001). Pain was significantly lower (2[1-2]) in Valsalva group compared to control (4[2–5]); (P < 0.001). CONCLUSIONS: Valsalva reduced both severity of venipuncture pain and anxiety. Valsalva can be performed by donors as it is an easy, painless, and nonpharmacological method of pain and anxiety attenuation. Wolters Kluwer - Medknow 2021 2021-06-12 /pmc/articles/PMC8294442/ /pubmed/34349460 http://dx.doi.org/10.4103/ajts.AJTS_95_20 Text en Copyright: © 2021 Asian Journal of Transfusion Science https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Srivastava, Anubha
Kumar, Sanjay
Agarwal, Anil
Khetan, Dheeraj
Katharia, Rahul
Mishra, Prabhaker
Khati, Shikha
Gautam, Sujeet
Sandeep, Khuba
Evaluation of efficacy of Valsalva for attenuating needle puncture pain in first time nonremunerated voluntary plateletpheresis donors: A prospective, randomized controlled trial
title Evaluation of efficacy of Valsalva for attenuating needle puncture pain in first time nonremunerated voluntary plateletpheresis donors: A prospective, randomized controlled trial
title_full Evaluation of efficacy of Valsalva for attenuating needle puncture pain in first time nonremunerated voluntary plateletpheresis donors: A prospective, randomized controlled trial
title_fullStr Evaluation of efficacy of Valsalva for attenuating needle puncture pain in first time nonremunerated voluntary plateletpheresis donors: A prospective, randomized controlled trial
title_full_unstemmed Evaluation of efficacy of Valsalva for attenuating needle puncture pain in first time nonremunerated voluntary plateletpheresis donors: A prospective, randomized controlled trial
title_short Evaluation of efficacy of Valsalva for attenuating needle puncture pain in first time nonremunerated voluntary plateletpheresis donors: A prospective, randomized controlled trial
title_sort evaluation of efficacy of valsalva for attenuating needle puncture pain in first time nonremunerated voluntary plateletpheresis donors: a prospective, randomized controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294442/
https://www.ncbi.nlm.nih.gov/pubmed/34349460
http://dx.doi.org/10.4103/ajts.AJTS_95_20
work_keys_str_mv AT srivastavaanubha evaluationofefficacyofvalsalvaforattenuatingneedlepuncturepaininfirsttimenonremuneratedvoluntaryplateletpheresisdonorsaprospectiverandomizedcontrolledtrial
AT kumarsanjay evaluationofefficacyofvalsalvaforattenuatingneedlepuncturepaininfirsttimenonremuneratedvoluntaryplateletpheresisdonorsaprospectiverandomizedcontrolledtrial
AT agarwalanil evaluationofefficacyofvalsalvaforattenuatingneedlepuncturepaininfirsttimenonremuneratedvoluntaryplateletpheresisdonorsaprospectiverandomizedcontrolledtrial
AT khetandheeraj evaluationofefficacyofvalsalvaforattenuatingneedlepuncturepaininfirsttimenonremuneratedvoluntaryplateletpheresisdonorsaprospectiverandomizedcontrolledtrial
AT kathariarahul evaluationofefficacyofvalsalvaforattenuatingneedlepuncturepaininfirsttimenonremuneratedvoluntaryplateletpheresisdonorsaprospectiverandomizedcontrolledtrial
AT mishraprabhaker evaluationofefficacyofvalsalvaforattenuatingneedlepuncturepaininfirsttimenonremuneratedvoluntaryplateletpheresisdonorsaprospectiverandomizedcontrolledtrial
AT khatishikha evaluationofefficacyofvalsalvaforattenuatingneedlepuncturepaininfirsttimenonremuneratedvoluntaryplateletpheresisdonorsaprospectiverandomizedcontrolledtrial
AT gautamsujeet evaluationofefficacyofvalsalvaforattenuatingneedlepuncturepaininfirsttimenonremuneratedvoluntaryplateletpheresisdonorsaprospectiverandomizedcontrolledtrial
AT sandeepkhuba evaluationofefficacyofvalsalvaforattenuatingneedlepuncturepaininfirsttimenonremuneratedvoluntaryplateletpheresisdonorsaprospectiverandomizedcontrolledtrial